Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines

BMC Genomics

Volumn 15, Issue 1, 2014, Pages

  Li, Liang ^a   Fridley, Brooke L ^b,c   Kalari, Krishna ^b   Niu, Nifang ^a   Jenkins, Gregory ^b   Batzler, Anthony ^b   Abo, Ryan P ^a   Schaid, Daniel ^b   Wang, Liewei ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cytidine analogues; Cytosine arabinoside; Expression array; Functional genomics; Gemcitabine; Genome wide association study; Genome wide SNPs; Lymphoblastoid cell lines; Translational research

Indexed keywords

CYTARABINE; DEOXYCYTIDINE; GEMCITABINE; GENETIC MARKER; MANNOSYLTRANSFERASE; PIGB PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; GENETICS; GENOTYPE; HUMAN; METABOLISM; REGULATORY SEQUENCE; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CYTARABINE; DEOXYCYTIDINE; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MANNOSYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; REGULATORY ELEMENTS, TRANSCRIPTIONAL; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84893165119     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-15-93     Document Type: Article

References (39)

1. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T, Ries RE, Lubman O, Fremont DH, McLellan MD, Payton JE, Westervelt P, DiPersio JF, Link DC, Walter MJ, Graubert TA, Watson M, Baty J, Heath S, Shannon WD, Nagarajan R, Bloomfield CD, Mardis ER, Wilson RK, Ley TJ. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008, 111:4797-4808. 10.1182/blood-2007-09-113027, 2343607, 18270328.
2. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992, 52:533-539.
3. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988, 48:4024-4031.
4. Kindler HL. In focus: advanced pancreatic cancer. Clin Adv Hematol Oncol 2005, 3:420-422.
5. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006, 107:116-124. 10.1002/cncr.21543, 16721819.
6. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990, 50:4417-4422.
7. Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, Cotsapas C, Xie X, Byrne EH, McCarroll SA, Gaudet R, Schaffner SF, Lander ES, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, et al. Genome-wide detection and characterization of positive selection in human populations. Nature 2007, 449:913-918. 10.1038/nature06250, 2687721, 17943131.
8. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008, 322:881-888. 10.1126/science.1156409, 2694957, 18988837.
9. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nothen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Hofels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy J, McMahon FJ. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008, 13:197-207. 10.1038/sj.mp.4002012, 2527618, 17486107.
10. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011, 364:1144-1153. 10.1056/NEJMra1010600, 3184612, 21428770.
11. Wang L, Weinshilboum RM. Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet 2008, 17:R174-R179. 10.1093/hmg/ddn270, 2574004,2574004, 18852207.
12. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Morizane C, Yamamoto N, Ikeda M, Yoshida T, Minami H, Furuse J, Ishii H, Saijo N, Kamatani N, Ozawa S, Sawada J. Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet 2006, 21:248-256. 10.2133/dmpk.21.248, 16858130.
13. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Ikeda M, Morizane C, Yamamoto N, Yoshida T, Kamatani N, Furuse J, Ishii H, Saijo N, Ozawa S, Sawada J. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet 2008, 23:379-384. 10.2133/dmpk.23.379, 18974616.
14. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC. Ribonucleotide reductase M1 (RRM1) 2464GA polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006, 16:429-438. 10.1097/01.fpc.0000204999.29924.da, 16708051.
15. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007, 25:32-42.
16. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005, 11:2620-2624. 10.1158/1078-0432.CCR-04-1497, 15814642.
17. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, Wang L. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008, 68:7050-7058. 10.1158/0008-5472.CAN-08-0405, 2562356, 18757419.
18. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, Wang L. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 2009, 4:e7765. 10.1371/journal.pone.0007765, 2770319, 19898621.
19. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010, 28:4674-4682. 10.1200/JCO.2010.28.5064, 3020700, 20876420.
20. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Goetz MP, Northfelt DW, Perez EA, Williard CV, Schaid DJ, Nakamura Y, Weinshilboum RM. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol 2013, 27:657-670. 10.1210/me.2012-1397, 23518928.
21. Liu M, Wang L, Bongartz T, Hawse JR, Markovic SN, Schaid DJ, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, Goss PE, Ingle JN, Weinshilboum RM. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res 2012, 14:R41. 10.1186/bcr3137, 3446375, 22405131.
22. Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Fridley B, Schaid D, Kamatani N, Nakamura Y, Kubo M, Mushiroda T, Kaddurah-Daouk R, Mrazek DA, Weinshilboum RM. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics 2012, 22:247-253. 10.1097/FPC.0b013e32835001c9, 3303952, 22322242.
23. Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M, Wu TY, Jenkins GD, Batzler A, Wang L. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res 2010, 20:1482-1492. 10.1101/gr.107672.110, 2963812, 20923822.
24. Browning SR, Browning BL. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 2007, 81:1084-1097. 10.1086/521987, 2265661, 17924348.
25. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA, 1000 Genomes Project Consortium An integrated map of genetic variation from 1,092 human genomes. Nature 2012, 491:56-65. 10.1038/nature11632, 3498066, 23128226, 1000 Genomes Project Consortium.
26. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003, 100:9440-9445. 10.1073/pnas.1530509100, 170937, 12883005.
27. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009, 16:259-266. 10.1016/j.ccr.2009.07.016, 2755578, 19732725.
28. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H, Ingle C, Beazley C, Gutierrez Arcelus M, Sekowska M, Gagnebin M, Nisbett J, Deloukas P, Dermitzakis ET, Antonarakis SE. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 2009, 325:1246-1250. 10.1126/science.1174148, 2867218, 19644074.
29. Takahashi M, Inoue N, Ohishi K, Maeda Y, Nakamura N, Endo Y, Fujita T, Takeda J, Kinoshita T. PIG-B, a membrane protein of the endoplasmic reticulum with a large lumenal domain, is involved in transferring the third mannose of the GPI anchor. EMBO J 1996, 15:4254-4261. 452151, 8861954.
30. Masterson WJ, Doering TL, Hart GW, Englund PT. A novel pathway for glycan assembly: biosynthesis of the glycosyl-phosphatidylinositol anchor of the trypanosome variant surface glycoprotein. Cell 1989, 56:793-800. 10.1016/0092-8674(89)90684-3, 2924349.
31. Doering TL, Masterson WJ, Hart GW, Englund PT. Biosynthesis of glycosyl phosphatidylinositol membrane anchors. J Biol Chem 1990, 265:611-614.
32. Sutterlin C, Escribano MV, Gerold P, Maeda Y, Mazon MJ, Kinoshita T, Schwarz RT, Riezman H. Saccharomyces cerevisiae GPI10, the functional homologue of human PIG-B, is required for glycosylphosphatidylinositol-anchor synthesis. Biochem J 1998, 332(Pt 1):153-159. 1219463, 9576863.
33. Guo Z, Linn JF, Wu G, Anzick SL, Eisenberger CF, Halachmi S, Cohen Y, Fomenkov A, Hoque MO, Okami K, Steiner G, Engles JM, Osada M, Moon C, Ratovitski E, Trent JM, Meltzer PS, Westra WH, Kiemeney LA, Schoenberg MP, Sidransky D, Trink B. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med 2004, 10:374-381. 10.1038/nm1010, 15034568.
34. Wu G, Guo Z, Chatterjee A, Huang X, Rubin E, Wu F, Mambo E, Chang X, Osada M, Sook Kim M, Moon C, Califano JA, Ratovitski EA, Gollin SM, Sukumar S, Sidransky D, Trink B. Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer. Cancer Res 2006, 66:9829-9836. 10.1158/0008-5472.CAN-06-0506, 17047043.
35. Kim DH, Jung HD, Kim JG, Lee J-J, Yang D-H, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006, 108:2720-2725. 10.1182/blood-2006-01-009480, 16609067.
36. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010, 10:389-402. 10.1038/nrc2867, 2950312, 20495573.
37. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol 2011, 21:354-361. 10.1016/j.tcb.2011.04.001, 21550244.
38. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004, 78:1893-1902. 10.1128/JVI.78.4.1893-1902.2004, 369434, 14747554.
39. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002, 62:1920-1926.